HCM
CASC

Highlander Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Highlander Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9,167
Closed -$90K – 874
2015
Q1 		$90K Buy
9,167
+1,667
+22% +$16.3K 0.08% 271
2014
Q4 		$86K Buy
+7,500
New +$81.4K 0.07% 279
2014
Q1 		– Sell
-1,083
Closed -$11.4K – 864
2013
Q4 		$11.4K Hold
1,083
– – 0.01% 621
2013
Q3 		$13.4K Buy
+1,083
New +$11.4K 0.01% 602

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highlander Capital Management's CASC Position: Q2 2015 in Review

Highlander Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 9,167 shares — an estimated $90K sold.

Highlander Capital Management first reported a position in CASC in Q3 2013 and held it in 4 quarters. The position peaked at $90K in Q1 2015. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

  • Highlander Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Highlander Capital Management sold 9,167 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $90K.
  • Highlander Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 4 quarters.
  • Highlander Capital Management's Cascadian Therapeutics, Inc. position peaked at $90K in Q1 2015.
  • 100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Highlander Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.